Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA₂DS₂-VASc Score 0–1: A Korean Multi-Center Cohort

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

“…Creatinine clearance was calculated using the Cockcroft–Gault formula, 17 and the LA dimension was measured in the M‐mode of the parasternal long axis view of transthoracic echocardiography 18 . According to the stratification method of thromboembolic risk in a previous study, the patients were categorized into two groups according to ABCD score and analyzed as follows: (1) ABCD score 0 and (2) ABCD score ≥1 19 . Patients enrolled in the study were further categorized based on types of ATT as follows: (1) aspirin or P2Y12 inhibitor (clopidogrel) as a single antiplatelet (SAPT) therapy, (2) vitamin K antagonist (VKA) therapy, and (3) non‐vitamin K antagonist oral anticoagulant (NOAC) therapy (apixaban, dabigatran, rivaroxaban, or edoxaban).…”

Coagulation Biomarkers for Predicting Clinical Outcomes Among Patients With Atrial Fibrillation

“…9 For the clinical application of biomarkers, the refinement of further risk stratification of clinical outcomes, particularly for those initially classified as low-risk with a nonsex CHA 2 DS 2 -VASc score of 0 or 1, would be noteworthy. 10 , 11 Therefore, the use of biomarkers may uncover truly low-risk patients with AF among those previously identified as at low risk of stroke.…”